Feasibility of Immunotherapy Plus Chemotherapy Administration to Patients With Bronchial Cancer in a Hospital-at- Home Setting - CombHADom
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 10
- 试验地点
- 1
- 主要终点
- Feasibility of home-based immunotherapy (percentage of patients who interrupted their home hospitalization for reasons directly linked to that management)
研究概览
简要总结
This observational prospective monosite study aims to describe, for the first time, management in a hospital-at-home programme of patients treated by immunotherapy-chemotherapy combo for bronchial cancer in maintenance phase of first row metastatic treatment.
The feasibility in good conditions of this management, the patients' quality of life and their satisfaction will be evaluated. A cost-benefit analysis will be done to compare hospital-at-home programme and classical day hospitalization.
详细描述
Those last years, immunotherapy treatment for bronchial cancers allowed considerable progress in terms of tumoral answer, survival without progression and global survival. Usually administered in the day hospitalization department, its preparation and administration to the patient are compatible with hospital-at-home management. This type of management has particularly developed in the context of the COVID pandemic and recommendations for good practices in hospital-at-home immunotherapy have recently been drafted by FITC (Société Française d'Immuno-Thérapie du Cancer). These recommendations open the way for administration of immunotherapy and chemotherapy combo in hospital-at-home. At the moment, there is no study stating the feasibility of home hospitalization for patients treated by immunotherapy-chemotherapy combo. To follow up on the feasibility study of home immunotherapy (ImHADom) carried out at CH Pau from March 2019 to March 2021, the sponsor propose to evaluate with descriptive study the feasibility under the same conditions of chemotherapy-immunotherapy in patients treated in the maintenance phase of a first metastatic row.
This study will be proposed to all the patients in maintenance phase of first row treatment with at least one positive tumoral imaging assessment (stable disease or partial response) for whom home hospitalization has been decided and scheduled by the healthcare team in a medical staff meeting.
The patients included in the study will be followed according to the common practice: a consultation every 3 months during 1 year.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients aged 18 and over,
- •with bronchial metastatic cancer treated in first row maintenance phase by immunotherapy-chemotherapy combo,
- •having at least one assessments of the response to immunotherapy received in day hospitalization with efficiency (stability or partial response),
- •without any graded higher than 1 adverse effects, or uncontrolled grade 1 adverse effects related to immunotherapy
- •eligible for a home-based hospitalization
排除标准
- •Frail patients requiring a frequent medical assessment thus day hospitalization cares
结局指标
主要结局
Feasibility of home-based immunotherapy (percentage of patients who interrupted their home hospitalization for reasons directly linked to that management)
时间窗: 1 year
Feasibility under good conditions of home-based immunotherapy, defined by the percentage of patients who interrupted their home hospitalization for reasons directly linked to that management.
次要结局
- Cost-benefit analysis(1 year)
- Quality of Life Questionnaire (EORTC QLQ-C30) total score(at inclusion, month 3, 6 9 and 12)
- Healthcare professional satisfaction(at month 6, 12, 18 and 24 of the study)
- Patients' Satisfaction Questionnaire(at month 3, 6 9 and 12)
- Number of adverse effects occuring during the study(1 year)
- Number of Incidents occurring during the Hospital at Home program handling process(1 year)